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Abstract
Background: This study aimed to evaluate the prognostic significance of expres-
sion levels of involucrin (IVL), cytokeratin (CK)-10 and -13 at different intratumor
sites (tumor center and invading area) of oral tongue squamous cell carcinoma
(OTSCC).
Methods: IVL, CK13 and CK10 expression levels were examined in a multi-
center cohort of 146 OTSCCs using immunohistochemistry. External mRNA
datasets were used for expression analysis and/or to validate survival
associations.
Results: External transcriptomic datasets showed downregulation of IVL
and KRT13 in oral malignancies including OTSCC as compared to normal
controls. The combined loss of IVL and CK13 expression at the invading
core but not at the center core was significantly associated with poor dif-
ferentiation and reduced 5-year overall survival. Multivariate Cox analysis
confirmed the loss of CK13 and IVL expression to be an independent
prognostic factor. Transcriptomic dataset corroborated immunohistochem-
istry results.
Conclusions: Combined expression levlels of IVL and CK13 might be useful
as prognostic biomarkers in OTSCC.
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1 | INTRODUCTION
Squamous cell carcinoma (SCC) of the tongue is one of the
most common malignancies of the oral cavity, representing
up to 50% of oral SCC.1,2 The incidence of tongue SCC has
been steadily increasing, whereas the incidence of oral SCC
(OSCC) in other anatomical subsites has been decreasing.3
Tongue SCC has an aggressive clinical behavior and is fre-
quently associated with lymph node involvement and poor
prognosis. Although the precise mechanism for aggressive
tongue SCC phenotype is not fully understood, the presence
of a rich lymphatic network and a highly muscularized
structure has been suggested to contribute to the increased
incidence of invasion and metastasis in tongue SCC.4–6
Topographically, tongue SCC can be divided into lesions
arising from the mobile/oral tongue (part of oral cavity) and
base of the tongue (part of oropharynx). SCC arising from
mobile/oral tongue is called oral tongue SCC (OTSCC).
Etiopathogenesis and prognosis of OTSCC are believed to
be different than that of SCC in the base of the tongue.7
Tobacco and alcohol are the main risk factors for OTSCC,
whereas the majority of SCC in the base of the tongue are
related to human papillomavirus (HPV) infection.7,8 Fur-
thermore, the prognosis of OTSCC is worse than that of
SCC in the base of the tongue.9 At the molecular level,
tobacco-associated OSCC, including OTSCC, is associated
with a significantly higher number of mutational events
probably attributed to tobacco and alcohol use as compared
to HPV-associated SCC in the base of the tongue.10 These
observations underscore the importance of stratification of
OTSCC from SCC at the base of the tongue, not only for bio-
marker studies but also for management purpose.
Among the various molecular changes occurring in
carcinomas in the head and neck region, including
OTSCC, mutations in genes such as TP53, FAT1,
NOTCH1, and deregulation of signaling pathways related
to keratinocyte differentiation represent key molecular
events.11,12 Accordingly, downregulation/loss of expression
of differentiation protein markers such as involucrin (IVL,
encoded by IVL gene) and members of the cytokeratin
(CK) protein family are frequent observations in OSCC.13–15
They have been linked to poor prognosis in OSCC/head
and neck SCC.16,17 Nevertheless, the expression patterns of
CK10 (encoded by KRT10 gene), CK13 (encoded by KRT13
gene), and IVL at different intratumor sites (tumor center
[more differentiated area] vs. invading front [less differenti-
ated area]) of OTSCC are currently unknown. In addition,
the prognostic significance of these proteins, either alone or
in combination, has not been previously examined in a
multicenter, HPV-negative homogenous cohort of OTSCC.
This study aimed at investigating the expression of
CK10, CK13, and IVL as putative biomarkers for
prognosis of OTSCC using immunohistochemistry on a
well-characterized multicenter retrospective patient
cohort. The results showed that the combined loss of
expression of IVL and CK13 at the deep/invading tumor
areas was associated with poor tumor differentiation and
reduced 5-year survival of patients with OTSCC. These
findings were further validated on mRNA data for
OTSCC from The Cancer Genome Atlas (TCGA).
2 | MATERIALS AND METHODS
2.1 | External microarray and TCGA
datasets
A microarray dataset (GSE30784)18 consisting of 45 normal
oral mucosa, 17 oral dysplasia, and 167 OSCC cases and
TCGA/The Genotype tissue expression (GTEx) datasets19
were used to compare mRNA expression levels of KRT10,
KRT13 and IVL in OSCC/head and neck SCC with normal
controls. The “box plot” tool in Gene Expression Profiling
Interactive Analysis (GEPIA)20 was used for TCGA/GTEx
datasets. Further, mRNA expression levels of IVL and
KRT13 from 523 cases of head and neck SCC in the TCGA
dataset were exported through cBioPortal.21,22 Of the
316 cases of OSCC, 114 HPV-negative specimens of OTSCC
were used to examine association between the combined
mRNA expression levels of KRT13 and IVL with clinico-
pathological variables and patient survival.
2.2 | Patient cohort
The study included 146 patients with diagnosed OTSCC
(all HPV-negative23). This study is a part of large patient
cohort in Norwegian Oral Cancer (NOROC) study,
including all consecutive patients, diagnosed and treated
at the three major hospitals treating head and neck can-
cer (Oslo, Bergen, and Tromsø) in Norway from January
1, 2005 till December 31, 2009 (Figure 1). Of the 146 cases,
128 were primary and 18 were second primary OTSCC.
Tissue microarrays (TMA) using tissue cores of 2 mm
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diameter from both invading front (the most deepest part
of an invasive tumor, henceforth called “invading core”)
and superficial/center areas (henceforth called “center
core”) were constructed using formalin-fixed paraffin
embedded (FFPE) specimens as described previously.23
Except for 18, the center and corresponding invading
cores were available for all of the cases. For 75 cases from
Oslo, duplicate cores were available for both center and
invading areas. The study was approved by the Northern
Norwegian Regional Committee for Medical Research
Ethics (REK nord, ref: 2015/1381). Tumors specimens
were classified following the 5th edition of the TNM clas-
sification.24 The following clinicopathological variables
were documented: age, sex, date of birth, date of diagno-
sis, habit history (smoking, alcohol), primary tumor site,
tumor size, node and metastasis, disease stage (both path-
ological and clinical), tumor differentiation, treatment
received, and recurrence history of the disease. In addi-
tion, date of death and cause of death were also retrieved
from patients' hospital record or from the Statistics of
Norway, Cause of Death Registry. Study adhered to
REMARKS guidelines25 where appropriate.
2.3 | Immunohistochemistry
IHC was performed at the Department of Oral Biology,
University of Oslo. IHC was performed for CK10, CK13
and IVL. The following primary antibodies were used:
rabbit monoclonal anti-CK 13 antibody (HPA030877,
Atlas antibodies, Bromma, Sweden) at 1:250 dilution;
mouse monoclonal anti-IVL (Clone SY5, I9018, Sigma,
MO) antibody at 1:4000 dilution; and mouse monoclonal
anti-CK10 antibody (sc-53 252, Santa-Cruz Biotechnol-
ogy, Dallas, TX) at 1:200 dilution. IHC was performed on
4-μm thick FFPE TMA sections following standard proce-
dures using DakoEnVision + Dual Link System-HRP
and visualized using 3, 30 diaminobenzidine (DAB)
solution (Dako, Glostrup, Denmark). Briefly, the sec-
tions were deparaffinized by placing in an incubator at
56C overnight, followed by two changes of xylene for
5 min each. Rehydration was performed by two
changes of absolute ethanol, 96%, and 70% ethanol for
3 min each. Antigen retrieval for all three proteins was
performed by treating the slides with Tris-EDTA
(pH 9.0) in a pressure cooker at 100C for 15 min and
90C for 10 s. The sections were blocked with 10% nor-
mal goat serum (X907, Dako, Glostrup, Denmark) in
3% bovine serum albumin in Tris-buffered saline
+0.1% Tween (TBST), and incubated with
corresponding primary antibodies for an hour at room
temperature. EnVision HRP-mouse (K400111-2 Dako,
Glostrup, Denmark) for CK10 and IVL, and -rabbit
(K400311-2, Dako, Glostrup, Denmark) for CK13 sec-
ondary antibodies were thereafter applied for 30 min at
room temperature. Sections were visualized using DAB
chromogen for 4 min and counterstained with hema-
toxylin. Slides were then dehydrated, immersed in
xylene and mounted. Lining epithelium (normal
and/or dysplastic) adjacent to OTSCC sections served
as positive tissue controls, while TBST instead of pri-
mary antibody served as a negative control for the sec-
ondary antibody. In addition, rabbit immunoglobulin
fraction, X0903 (Dako, Glostrup, Denmark) for CK13
and IgG1 M9269 (Sigma, St. Louis, MO) for CK10 and
IVL were used as isotype-matched controls to control
for nonspecific binding of the primary antibodies. The
presence of a red-brown cytoplasmic staining was con-
sidered positive, regardless of the intensity.
2.4 | Digital image acquisition and
evaluation of immunohistochemistry
TMA-slides were scanned at 40 using Pannoramic MIDI
scanner (3DHISTECH, Budapest, Hungary). Afterward,
QuPath software version 0.2.0-m826 was used for visualiza-
tion and subsequent analysis of IHC. Lost/destroyed tissue
cores during IHC and cores with insufficient tumor cells or
with poor image quality were excluded from the analysis. As
FIGURE 1 Flowchart illustrating the origin and number of specimens (center and invading cores) used for IHC. One hundred and
forty-six OTSCC specimens were used to construct TMA. After exclusion of lost/destroyed tissue cores during IHC and cores with
insufficient tumor cells or with poor image quality, the numbers of specimens used for statistical analyses were different for different
proteins as shown in the flowchart [Color figure can be viewed at wileyonlinelibrary.com]
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shown in Figure 1, the total number of cores available for
analysis of IVL/CK13/CK10 was 143/142/137 at tumor cen-
ter and 127/128/123 at the invading area, respectively.
Blinded for clinicopathological information, IHC
evaluation was performed by S.P. and D.S. Prior to evalu-
ation, observers (S.P., D.S., and B.T.) had agreed upon
calibration and interpretation of immunostaining. All
tumor cells, both at the center and invading cores, were
used for IHC evaluation. Keratin pearls, stromal compo-
nents or background artifacts in tumor area were
excluded from IHC evaluation. Positive tumor cells
were presented as percentages of total number of tumor
cells. For cases with duplicate cores, an average of the
percentage of positive cells was calculated. The same
scoring system was applied for all three protein markers.
2.5 | Statistical analysis
Data are expressed as mean ± standard error of the mean.
Wilcoxon matched-pairs signed rank test was used to com-
pare immunoexpression in center versus corresponding
invading cores. Mann–Whitney test was used to compare
immunoexpression of each protein between primary and sec-
ond primary OTSCC and to examine the immunoexpression
with respect to the degree of tumor differentiation. Analysis
of variance (ANOVA)with Tukey's post hoc tests was used to
examine mRNA expression levels of KRT10, KRT13 and IVL
inmicroarray dataset. OTSCC cases were stratified into high-
and low-expression groups using mean expression values of
the respective protein markers as cutoff points. Association
between the expression of protein markers and clinicopatho-
logical parameters was examined using chi-square/Fischer
exact test. Kaplan–Meier survival analysis with log-rank tests
was performed to examine the association between the
expression status of proteins and patient survival. Univariate
and multivariate Cox-regression models were used to study
the effect of protein expression and other covariates on
patient survival. STATA version 16/GraphPad prism version
9.0.0/R studio version 1.3.959was used for statistical analysis.
p-Value of <0.05was considered statistically significant.
3 | RESULTS
3.1 | mRNA expression levels of IVL
and KRT13 were significantly
downregulated in OSCC/head and neck
SCC as compared to normal controls in
microarray and TCGA datasets
The mRNA expression levels of IVL and KRT13 were
found to be down-regulated in OSCC/head and neck SCC
specimens than in normal controls (Figure 2(A,B)). The
KRT10 mRNA expression was higher in cancer lesions as
compared to normal control both in OSCC and head and
neck SCC. Of interest, the expression levels of IVL and
KRT13 was similar between normal controls and oral
dysplasia, while KRT10 mRNA expression was signifi-
cantly upregulated in oral dysplasia as compared to nor-
mal controls (Figure 2(A)).
3.2 | Expression levels of IVL, CK13, and
CK10 were similar between primary
and second primary OTSCC
Expression levels of IVL, CK13, and CK10 were simi-
lar between primary and second primary lesions, both
at center and the corresponding invading cores
(Figure S1). Hence, in the subsequent analysis, the
second primary lesions were analyzed together with
primary lesions.
3.3 | Expression levels of IVL and CK13
were downregulated at invading cores as
compared to corresponding center cores in
OTSCC
Except for occasional stromal and inflammatory cells,
IVL, CK13 and CK10 were predominantly expressed by
the tumor cells. All protein markers showed mostly
cytoplasmic expression (Figure 3(A–F)). Percentage of
positive tumor cells was found to be highest for IVL
both at center (mean = 63.5% ± 2.2) and invading cores
(mean = 56% ± 2.7) (Figure 3(G)) as compared to that
of CK13 (24% ± 2.2 at center and 18% ± 2.3 at invading
cores) (Figure 3(H)) and CK10 (10% ± 1.5 at center and
9% ± 1.4 at invading cores) (Figure 3(I)). Expression
levels of IVL (p = 0.008) and CK13 (p = 0.017) at the
invading cores were significantly downregulated as
compared to the corresponding center cores (Figure 3
(G,H)). Expression of CK10 was found to be similar at
both the center and corresponding invading cores
(Figure 3(I)).
3.4 | Loss of CK13 and IVL expression at
the invading cores was associated with
poor tumor differentiation and poor 5-year
overall survival of patients with OTSCC
The IVL and CK13 expression and clinicopathological
characteristics of the cohort are summarized in Tables S1
and S2, Supporting Information. Briefly, the median age
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of OTSCC cases was 66 years and the male to female
ratio was 1.6:1. Using chi-square test, OTSCC with
lower expression of IVL (p = 0.001) or CK13 (p =
0.004) at the invading core were found to be signifi-
cantly associated with poor tumor differentiation
(Tables S1 and S2). In parallel with these results, with
Mann–Whitney test, the expression levels of both IVL
and CK13 at the invading cores were found to be signif-
icantly higher in well/moderately differentiated lesions
as compared to the poorly differentiated tumors
(Figure 4(A,B)). IVL expression at center core was sim-
ilar between well/moderately and poorly differentiated
OTSCC, while CK13 was significantly downregulated
in poorly differentiated OTSCC (Figure S2). CK10
expression levels at both center and invading cores
were not significantly different with respect to differen-
tiation status of OTSCC (Figure S3). As the expression
of CK10 was not significantly different with respect to
location (center vs. invading) (Figure 3(C)) and differ-
entiation status (well/moderate vs. poor differentia-
tion) (Figure S3), only the expression status of IVL and
CK13 at invading cores was considered in the further
analysis.
Kaplan–Meier plot showed a reduced 5-year overall
(log-rank test, p = 0.04) and disease-specific (log-rank,
p = 0.03) survival probabilities for patients with low IVL
expression at the invading cores (Figures S4 and S5).
Despite similar trends, expression of CK13 at the
FIGURE 2 In microarray transcriptome dataset (A), mRNA expression levels of IVL and KRT13 were significantly downregulated in
OSCC as compared to normal oral mucosa/oral dysplasia. However, KRT10 was slightly upregulated in OSCC as compared to the normal
oral mucosa. In TCGA dataset (B), mRNA expression levels of IVL and KRT13 were downregulated, whereas KRT10 was slightly upregulated
in head and neck SCC as compared to the normal controls [Color figure can be viewed at wileyonlinelibrary.com]
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invading core was not statistically associated either with
5-year overall (log-rank, p = 0.12) or with disease-specific
survivals (p = 0.21) (Figures S6 and S7). No association
was found between expression of IVL or CK13 at the
invading cores and recurrence-free survival (Figure S8).
We next examined the performance of combined
expression of IVL and CK13 at invading cores in predicting
survival of patients with OTSCC. OTSCC cases were strati-
fied into high combined expression group (high expression
of both IVL and CK13, referred to as IVLhigh + CK13high)
and low combined expression group (low expression of both
IVL and CK13, referred to as IVLlow + CK13low) by using
corresponding mean expression scores as cut-off points.
IVLlow + CK13low, IVLhigh + CK13high, and mixed group
either IVLlow + CK13high or IVLhigh + CK13low consisted of
41, 38 and 48 OTSCC cases, respectively. Kaplan–Meier cur-
ves for the three groups showed that IVLlow + CK13low
OTSCC cases had the lowest survival probabilities than for
the mixed and high groups (Figure 4(E)) (log-rank,
p = 0.12). However, when only high and low groups were
analyzed, IVLhigh + CK13high cases were found to have sig-
nificantly higher (log-rank test, p = 0.03) survival probabili-
ties than that of IVLlow + CK13low group (Figure 4(F)).
Of note, the expression levels of IVL and CK13 either
alone or in combination at the center cores were not sta-
tistically associated with patient survival.
FIGURE 3 Representative
images showing expression
patterns of IVL (A, B), CK13 (C,
D), and CK10 (E, F) at the
center and corresponding
invading cores. All protein
markers showed predominantly
cytoplasmic expression in the
tumor cells. Quantification of
immunostaining showed
significantly fewer positive cells
at the invading core for IVL (G,
p = 0.008) and CK13 (H,
p = 0.017) as compared to the
corresponding center cores.
Expression of CK10 (I, p > 0.05)
was similar both at the tumor
center and the corresponding
invading core. Wilcoxon
matched-pairs signed rank test
was used for statistical analysis
in (G–I). Horizontal bars
represent means of expression
values. ns; nonsignificant. IHC
images were exported from
QuPath software at 60x [Color
figure can be viewed at
wileyonlinelibrary.com]
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3.5 | Combination of CK13 and IVL
expression as an independent prognostic
factor to predict survival of patients with
OTSCC in Cox proportional hazards
regression analysis
Univariate Cox analysis showed low combined expres-
sion of IVL and CK13 at invading cores, increased tumor
size (clinical), node involvement (clinical), and late clini-
cal stage to be significant risk factors for reduced 5-year
overall survival (Table 1). Multivariate Cox regression
analysis using variables as described in Table 1 demon-
strated combined CK13 and IVL expression at invading
core to be an independent prognostic factor for 5-year
survival of patients with OTSCC (HR = 0.38, CI = 0.17–
0.85, p = 0.02) (Table 1). The test of proportional-hazards
FIGURE 4 A significantly
greater number of positive cells
for IVL (A, p < 0.0001) and
CK13 (B, p = 0.0003) were
found at the invading core in
well/moderately differentiated
OTSCC as compared to the
poorly differentiated lesions.
Mann–Whitney test was used for
statistical analysis. Horizontal
bars represent the means of
expression values. The error bars
represent SEM. Representative
images showing OTSCC cases
with high (C) and low (D)
combined expression of IVL and
CK13. IHC images were
exported from QuPath software
at 60x. (E) Kaplan–Meier plot
demonstrating 5-year overall
survival curves for high
(IVLhigh + CK13high), low
(IVLlow + CK13low), and mixed
group (IVLlow + CK13high) or
(IVLhigh + CK13low) (log-rank
test, p = 0.12). (F) Kaplan–Meier
plot showed a significantly
higher (log-rank test, p = 0.035)
5-year overall survival for high
(IVLhigh + CK13high) group as
compared to the low
(IVLlow + CK13low) group
[Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 1 Univariate and
multivariate Cox proportional hazards
regression analysis for combined
expression of IVL and CK13 and
clinicopathological covariates
Variables
Univariate Cox Multivariate Cox
HR 95% CI p-value HR 95% CI p-value
IVL + CK13 expressiona
Low 1.00 1.00
High 0.50 0.26–0.96 0.04 0.38 0.17–0.85 0.02
Ageb
≤66 1.00 1.00
>66 1.8 0.96–3.38 0.06 1.30 0.64–2.66 0.73
Differentiationc
Well 1.00 1.00
Moderate and poor 1.20 0.63–2.30 0.56 0.75 0.36–1.60 0.46
Clinical staged
Early (1 and 2) 1.00 1.00
Late (3 and 4) 3.24 1.68–6.24 <0.00 2.00 0.33–11.90 0.45
Clinical tumor sizee
Smaller 1.00 1.00
Larger 3.66 1.66–8.10 0.001 1.8 0.52–6.80 0.34
Node statusf
Negative 1.00 1.00
Positive 2.66 1.28–5.25 0.008 1.80 0.34–9.31 0.48
Note: The values marked in bold indicate that they were less than the level of significance (0.05) used for the
statistical analysis.
Abbreviations: CI, confidence interval; HR, hazard ratio.
aOTSCCs were stratified into high (IVLhigh + CK13high) and low (IVLlow + CK13low) expression groups by
using corresponding mean expressions as cut-off points.
bPatients were categorized into low- and high-age groups based on the median age.
cOTSCC were categorized into well/moderate and poor differentiated groups.
dPatients were categorized into early (stage I-II) and late (stage III-IV) using clinical TNM staging.
eTumors were categorized into smaller (T1 and T2) and larger (T3 and T4) tumors using clinical tumor size.
fTumors were categorized into node positive (N1 and N2) and negative (N0) groups using clinical node status.
FIGURE 5 (A) Kaplan–Meier curves showing reduced 5-year overall survival for patients with low combined mRNA expression of IVL and
KRT13 (log-rank test, p = 0.049). The risk table B showed absolute number of cases at risk for both combined high and low expression groups at
different time points, and C showed number of censored subjects at different months [Color figure can be viewed at wileyonlinelibrary.com]
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assumption using global test showed that there was no
deviation from proportionality (p > 0.05) (Table S3).
3.6 | Low combined mRNA expression of
IVL and KRT13 was associated with poor
tumor differentiation and reduced 5-year
overall survival of OTSCC cases in TCGA
datasets
HPV-negative OTSCC cases from TCGA datasets were
stratified into high and low expression groups by using
median expression values of IVL or KRT13 as cut-off
points. Median values were used due to significant scatter
of IVL or KRT13 mRNA levels. The number of cases with
high and low combined expression was 38 and 37
(Figure 5). Parallel to the IHC results, the low combined
group was significantly associated (p = 0.002) with poor
tumor differentiation (Table 2). In addition, the Kaplan–
Meier survival analysis showed that low combined
mRNA expression of IVL and KRT13 was significantly
associated with reduced overall 5-year survival as com-
pared to the combined high expression group (log-rank
test, p = 0.049) (Figure 5).
4 | DISCUSSION
During the normal differentiation process of oral epithe-
lium, keratinocytes undergo a series of biochemical and
morphological changes leading to accumulation of an
array of filamentous proteins (differentiation markers)
such as CKs and IVL.27,28 The control of epithelial differ-
entiation is deregulated in human epithelial malignancies
and accordingly altered expression patterns of a number
of differentiation markers are frequently observed in
OSCC.11 However, the prognostic significance of altered
expression patterns of CK10, CK13 and IVL, either alone
or in combination, at different intratumor sites (tumor
center and invading area) in a homogenous cohort of
OTSCC is not known. The current study, using IHC for
CK10, CK13 and IVL in TMA on a large OTSCC cohort,
revealed that the reduced combined expression of IVL
and CK13 at invading cores was associated with poor
tumor differentiation and poor prognosis. These findings
were further validated by analyzing mRNA expression
levels of IVL and KRT13 genes in TCGA dataset for
OTSCC.
Using microarray and TCGA transcriptomic datasets,
mRNA expression levels of IVL and KRT13 were found to
TABLE 2 Association between the
combined expression IVL and KRT13
mRNA and clinicopathological
variables of the patients with OTSCC in
TCGA dataset
Variables
Combined mRNA expression of IVL and KRT13a
Low, n (%) High, n (%) p-value
Ageb (years)
≤60 21 (52.0) 19 (47.5) 0.558
>60 16 (45.7) 19 (54.2)
Sex
Female 16 (48.4) 17 (48.4) 0.89
Male 21 (50.0) 21 (50.0)
Differentiation (WHO classification, whole tumor)c
Well 01 (00.7) 12 (92.3) 0.002
Moderate 27 (55.0) 22 (45.0)
Poor 09 (69.2) 04 (30.7)
Lymph node involvementd
Negative 15 (41.6) 21 (58.4) 0.20
Positive 22 (56.5) 17 (43.5)
Tumor sizee
Smaller (1 and 2) 18 (47.3) 20 (52.7) 0.73
Larger (3 and 4) 19 (51.3) 18 (48.7)
Note: The values marked in bold indicate that they were less than the level of significance (0.05) used for the
statistical analysis.
aOTSCCs were stratified into high and low groups using combined mRNA expression levels of IVL and
KRT13 by using corresponding median expression values as cut-off points.
bPatients were categorized into low- and high-age groups based on the median age.
cOTSCC were categorized into well, moderate, and poor differentiated groups.
dTumors were categorized into node positive (N1 and N2) and negative (N0) groups using clinical node status.
eTumors were categorized into smaller (T1 and T2) and larger (T3 and T4) cases using clinical tumor size.
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be significantly downregulated in OSCC/head and neck
SCC as compared to normal controls (Figure 2(A,B)).
Interestingly, their expression levels were similar in nor-
mal controls and oral dysplasia (Figure 2(A)), despite
some previous studies that have shown a downregulation
of CK13 or IVL in dysplastic lesions compared to normal
controls.29–31 This discrepancy could be due to different
methods used for expression analysis or due to variation
in the grade of dysplasia of the specimens used. In con-
trast, the upregulation of CK10 mRNA already in oral
dysplasia and OSCC/head and neck SCC (Figure 2(A,B))
suggests that its upregulation might be an early event in
OSCC. Overall, in accordance with previous reports,32
these findings suggest that dysregulation in differentia-
tion is a common event in OSCC.
The current study further corroborates evidence that
the expression levels of CK13 and IVL are related to the
differentiation status of malignant keratinocytes in
OTSCC. First, the expression levels of IVL and CK13
were downregulated at the invading cores, a poorly dif-
ferentiated area of a tumor33 as compared to the
corresponding center cores in OTSCC (Figure 3(G,H)).
Second, lower combined expression of IVL and CK13 was
significantly associated with poor tumor differentiation
(Table 2). In line with this, the expression levels of CK13
and IVL at invading cores were found to be significantly
lower in poorly differentiated OTSCC as compared to the
well/moderately differentiated lesions (Figure 4(A,B)).
Consistent with our results, previous studies have shown
positive associations between the expression of CK13 and
IVL with tumor differentiation in SCC, including
OSCC.34–36 Nevertheless, the lack of association of CK10
expression with tumor differentiation is in contrast to a
previous report in OSCC.34,37 This discrepancy could be
related to the location of lesions in the oral cavity as the
expression of CK10 has been shown to vary with anatom-
ical sites and the degree of keratinization of oral epithe-
lium.38,39 Besides this, the region of tumor tissue chosen
for evaluation of CK10 might be related to this discor-
dance as we have used TMA while Sadafi et al. and Bloor
et al. have used whole sections.
OTSCC/OSCC cases with poorly differentiated pheno-
type have been shown to have poor prognosis.40,41 In agree-
ment with these observations, OTSCC cases with combined
loss of CK13 and IVL expression at invading cores was sig-
nificantly associated with poorer 5-year overall survival
(Figure 4(E,F)). Multivariate Cox regression analysis further
indicated that the combined loss of IVL and CK13 at invad-
ing core was an independent prognostic factor (HR = 0.38,
CI = 0.17–0.85, p = 0.02) in OTSCC. Although the prognos-
tic significance of IVL expression alone or in combination
with CK13 was not available in literature, in line with our
findings, the loss of expression of CK13 has been linked
with poor prognosis in tongue SCC.16,17 The IHC results
were paralleled by analysis of TCGA dataset where OTSCC
cases with low combined expression of IVL and CK13
mRNA levels were found to have significantly lower 5-year
overall survival probabilities (Figure 5).
The strength of this study is the use of multicenter,
HPV-negative homogenous specimens of OTSCC rep-
resenting the Norwegian population. Although often
overlooked, a significant molecular and prognostic het-
erogeneity among carcinomas from different anatomical
sites in oral cavity has been described10,42,43 and this is
particularly important to keep in mind for biomarker
studies. Moreover, evaluation of both center and invading
cores suggested that there is a significant intratumoral
heterogeneity with respect to the expression of CK13 and
IVL. Taken together, these suggestions emphasize that
measures should be taken to minimize the influence of
intrasite and intratumoral heterogeneity during bio-
marker/translational studies. On the other hand, the use
of tissue cores representing specific areas rather than the
whole tumor section can be considered as a potential
selection bias/limitation of the study. Nevertheless, dupli-
cate cores for both center and invading areas were avail-
able for more than 50% of the cases. In addition, as the
specimens used in the current study being a representa-
tive cohort of Norwegian population, the external validity
of the results of the study should be verified in popula-
tion with differing race, lifestyles, and habitual risk fac-
tors as compared to that of the Norwegian population.
In conclusion, our results further substantiated the
fact that the expression status of IVL and CK13 might be
useful as markers of differentiation in malignant oral
keratinocytes, as evidenced by the loss of expression at
the invading cores and in poorly differentiated lesions. In
addition, the combined expression status of IVL and
CK13 at the invading cores, but not at the tumor center,
might be potentially useful in predicting the prognosis of
patients with OTSCC. These findings could have implica-
tions in management of and further research initiatives
in OTSCC. However, further confirmatory studies using
whole tissue sections with a wide panel of differentiation
markers and including functional studies will further aid
in confirming the relevance of these dysregulated pro-
teins in OTSCC.
ACKNOWLEDGMENTS
We would like to thank Olav Jetlund (Oslo University Hos-
pital, Oslo), Ellen Jaatun (St. Olavs Hospital, Trondheim)
and Asa Karlsdottir (Haukeland University Hospital, Ber-
gen) for their contributions to recording of patient medical
records in the web-based CRF. We would like to thank
Helene Laurvik and Peter Jebsen (Oslo), Lars Uhlin-Hansen
and Sonja Eriksson Steigen (Tromsø), Elisabeth Sivy
10 PANDEY ET AL.
Nginamau (Bergen) and Håkon Hov (Trondheim) for their
contributions in the collection of tissue blocks, verification
of the pathological diagnosis in the CRF, and evaluation
and recording of histopathological features of the tumor tis-
sue in the CRF. For the tissue microarray generation, we
thank Peter Jebsen (Oslo), Elisabeth Sivy Nginamau
(Bergen), Lars Uhlin-Hansen and Sonja Eriksson Steigen
(Tromsø) for the identification and labeling of the regions
of interest. We thank Lisa Yuen Løvold (Oslo University
Hospital) for the technical assistance in the construction of
microarray blocks. We would like to thank Evan Michael
Vallenari (UiO, IOB) for his valuable contribution in lan-
guage editing. This work was supported by Helse Nord,
Norway (SFP1276-16), Siftelsen til tannlegevitenskapens
fremme (LPS), and the Institute of Oral Biology (DS),
Faculty of Dentistry, University of Oslo, Norway.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that
could be perceived as prejudicing the impartiality of the
research reported.
AUTHOR CONTRIBUTIONS
Dipak Sapkota, Burcu Senguven, and Daniela Elena
Costea conceived and designed research. Dipak Sapkota,
Tine Merete Søland, Lars Peter Sand, IngerHeidi Bjerkli,
Daniela Elena Costea, and Fernanda Cristina Petersen
contributed with specimens and reagents. Sushma Pan-
dey and Burcu Senguven performed the experiments.
Sushma Pandey and Burcu Senguven analyzed the data.
Sushma Pandey and Dipak Sapkota wrote the manu-
script. All coauthors critically reviewed and revised the
manuscript. Dipak Sapkota, Daniela Elena Costea, and
Fernanda Cristina Petersen supervised the work. All
authors read and approved the manuscript.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are avail-




Tine Merete Søland https://orcid.org/0000-0003-1687-
3247




1. Bjerkli IH, Jetlund O, Karevold G, et al. Characteristics and
prognosis of primary treatment-naïve oral cavity squamous cell
carcinoma in Norway: a descriptive retrospective study. PLoS
One. 2020;15(1):e0227738.
2. Rikardsen OG, Bjerkli I-H, Uhlin-Hansen L, Hadler-Olsen E,
Steigen SE. Clinicopathological characteristics of oral squa-
mous cell carcinoma in northern Norway: a retrospective
study. BMC Oral Health. 2014;14(1):103.
3. Vigneswaran N, Williams MD. Epidemiologic trends in head
and neck cancer and aids in diagnosis. Oral Maxillofac Surg
Clin North Am. 2014;26(2):123-141.
4. Hamiter M, Asarkar A, Rogers D, et al. A pilot study of merkel
cell polyomavirus in squamous cell carcinoma of the tongue.
Oral Oncol. 2017;74:111-114.
5. Lim MS. RE: correlational of oral tongue cancer inversion with
matrix metalloproteinases (MMPs) and vascular endothelial
growth factor (VEGF) expression, by Kim S-H, Cho NH,
Kim K, et al. J Surg Oncol. 2006;93(4):253-254.
6. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue
cancer: means, markers and perspectives (I). Oral Oncol. 2010;
46(9):630-635.
7. El-Naggar AC J, Grandis J, Takata T, Slootweg P. WHO Classi-
fication of Head and Neck Tumours. 4th ed. Lyon: IARC Press;
2017.
8. Mehanna H, Beech T, Nicholson T, et al. Prevalence of human
papillomavirus in oropharyngeal and nonoropharyngeal head
and neck cancer—systematic review and meta-analysis of
trends by time and region. Head Neck. 2013;35(5):747-755.
9. Fakhry C, Westra WH, Li S, et al. Improved survival of patients
with human papillomavirus-positive head and neck squamous
cell carcinoma in a prospective clinical trial. J Natl Cancer Inst.
2008;100(4):261-269.
10. Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive
genomic characterization of head and neck squamous cell car-
cinomas. Nature. 2015;517(7536):576-582.
11. Dotto GP, Rustgi AK. Squamous cell cancers: a unified perspec-
tive on biology and genetics. Cancer Cell. 2016;29(5):622-637.
12. Vettore AL, Ramnarayanan K, Poore G, et al. Mutational land-
scapes of tongue carcinoma reveal recurrent mutations in genes of
therapeutic and prognostic relevance.GenomeMed. 2015;7(1):98.
13. Sakamoto K, Aragaki T, Morita K, et al. Down-regulation of
keratin 4 and keratin 13 expression in oral squamous cell carci-
noma and epithelial dysplasia: a clue for histopathogenesis.
Histopathology. 2011;58(4):531-542.
14. Mikami T, Cheng J, Maruyama S, et al. Emergence of keratin
17 vs. loss of keratin 13: their reciprocal immunohistochemical
profiles in oral carcinoma in situ. Oral Oncol. 2011;47(6):497-503.
15. Itoiz ME, Conti CJ, Gimenez IB, Lanfranchi HE, Fernandez-
Alonso GI, Klein-Szanto AJ. Immunodetection of involucrin in
lesions of the oral mucosa. J Oral Pathol. 1986;15(4):205-208.
16. Yanagawa T, Yoshida H, Yamagata K, et al. Loss of cytokeratin
13 expression in squamous cell carcinoma of the tongue is a
possible sign for local recurrence. J Exp Clin Cancer Res. 2007;
26(2):215-220.
17. Xu ES, Yang MH, Liu CY, et al. Decreasing cytokeratin
17 expression in head and neck cancer predicts nodal metasta-
sis and poor prognosis: the first evidence. Clin Otolaryngol.
2018;43:1010-1018.
18. Chen C, Méndez E, Houck J, et al. Gene expression profiling
identifies genes predictive of oral squamous cell carcinoma.
Cancer Epidemiol Biomarkers Prev. 2008;17(8):2152-2162.
PANDEY ET AL. 11
19. Human Genomics. The genotype-tissue expression (GTEx)
pilot analysis: multitissue gene regulation in humans. Science.
2015;348(6235):648-660.
20. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web
server for cancer and normal gene expression profiling and
interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-
W102.
21. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics
portal: an open platform for exploring multidimensional cancer
genomics data. Cancer Discov. 2012;2(5):401-404.
22. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of
complex cancer genomics and clinical profiles using the
cBioPortal. Sci Signal. 2013;6(269):pl1.
23. Søland TM, Bjerkli I-H, Georgsen JB, et al. High-risk human
papilloma virus was not detected in a Norwegian cohort of oral
squamous cell carcinoma of the mobile tongue. Clin Exp Dent
Res. 2020;7(1):70-77.
24. Wittekind C, Hutter RVP, Klimpfinger M, Sobin LH. TNM
Atlas: Illustrated Guide to the TNM/pTNM Classification of
Malignant Tumours. 5th ed. New York, NY: Springer; 2005.
25. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting
recommendations for tumor marker prognostic studies
(REMARK): explanation and elaboration. PLoS Med. 2012;9(5):
e1001216.
26. Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: open
source software for digital pathology image analysis. Sci Rep.
2017;7(1):16878.
27. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The cat-
alog of human cytokeratins: patterns of expression in normal
epithelia, tumors and cultured cells. Cell. 1982;31(1):11-24.
28. Thomson P. Oral Precancer: Diagnosis and Management of
Potentially Malignant Disorders. Hoboken, NJ: John Wiley &
Sons; 2012.
29. Matsuhira A, Noguchi S, Sato K, et al. Cytokeratin
13, cytokeratin 17, Ki-67 and p53 expression in upper layers of
epithelial dysplasia surrounding tongue squamous cell carci-
noma. Bull Tokyo Dent Coll. 2015;56(4):223-231.
30. Kaplan MJ, Mills SE, Rice RH, Johns ME. Involucrin in laryn-
geal dysplasia. A marker for differentiation. Arch Otolaryngol.
1984;110(11):713-716.
31. Eisenberg E, Murphy GF, Krutchkoff DJ. Involucrin as a diag-
nostic marker in oral lichenoid lesions. Oral Surg Oral Med
Oral Pathol. 1987;64(3):313-319.
32. Ida-Yonemochi H, Maruyama S, Kobayashi T, Yamazaki M,
Cheng J, Saku T. Loss of keratin 13 in oral carcinoma in situ: a
comparative study of protein and gene expression levels using
paraffin sections. Mod Pathol. 2012;25(6):784-794.
33. Bryne M. Prognostic value of various molecular and cellular
features in oral squamous cell carcinomas: a review. J Oral Pat-
hol Med. 1991;20(9):413-420.
34. Safadi RA, Abdullah NI, Alaaraj RF, et al. Clinical and histo-
pathologic prognostic implications of the expression of
cytokeratins 8, 10, 13, 14, 16, 18 and 19 in oral and oropharyn-
geal squamous cell carcinoma. Arch Oral Biol. 2019;99:1-8.
35. Naganuma K, Hatta M, Ikebe T, Yamazaki J. Epigenetic alter-
ations of the keratin 13 gene in oral squamous cell carcinoma.
BMC Cancer. 2014;14(1):988.
36. Suo Z, Holm R, Nesland JM. Squamous cell carcinomas. An
immunohistochemical study of cytokeratins and involucrin in
primary and metastatic tumours. Histopathology. 1993;23(1):
45-54.
37. Bloor BK, Seddon SV, Morgan PR. Gene expression of
differentiation-specific keratins in oral epithelial dysplasia and
squamous cell carcinoma. Oral Oncol. 2001;37(3):251-261.
38. Rao RS, Patil S, Ganavi BS. Oral cytokeratins in health and dis-
ease. J Contemp Dent Pract. 2014;15(1):127-136.
39. Presland RB, Dale BA. Epithelial structural proteins of the skin
and oral cavity: function in health and disease. Crit Rev Oral
Biol Med. 2000;11(4):383-408.
40. Bjerkli I-H, Hadler-Olsen E, Nginamau ES, et al. A combined
histo-score based on tumor differentiation and lymphocytic
infiltrate is a robust prognostic marker for mobile tongue can-
cer. Virchows Arch. 2020;477(6):865-872.
41. Lin NC, Hsu JT, Tsai KY. Survival and clinicopathological
characteristics of different histological grades of oral cavity
squamous cell carcinoma: a single-center retrospective study.
PLoS One. 2020;15(8):e0238103.
42. Zelefsky MJ, Harrison LB, Fass DE, et al. Postoperative radio-
therapy for oral cavity cancers: impact of anatomic subsite on
treatment outcome. Head Neck. 1990;12(6):470-475.
43. Severino P, Alvares AM, Michaluart P Jr, et al. Global gene
expression profiling of oral cavity cancers suggests molecular
heterogeneity within anatomic subsites. BMC Res Notes. 2008;
1:113.
SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of this
article.
How to cite this article: Pandey S, Søland TM,
Bjerkli IH, et al. Combined loss of expression of
involucrin and cytokeratin 13 is associated with
poor prognosis in squamous cell carcinoma of
mobile tongue. Head & Neck. 2021;1-12. https://
doi.org/10.1002/hed.26826
12 PANDEY ET AL.
